Autosomal dominant polycystic kidney disease
ICD-10 Q61.2 · ICD-11 GB81

Treatment of ADPKD with eGFR ≥30 ml/min per 1.73 m²

This protocol applies to patients with autosomal dominant polycystic kidney disease (ADPKD) who have an eGFR of at least 30 ml/min per 1.73 m² and no contraindication to excreting a solute load. It defines a first-line management approach for this specific clinical situation.

Clinical scenario ADPKD with eGFR ≥30 ml/min per 1.73 m² and no contraindication to excreting a solute load. Preserved kidney function in this range makes certain first-line interventions feasible that would otherwise require closer monitoring or dose adjustment.
Treatment approach (partial) The first-line protocol centres on a structured daily fluid management strategy, timed throughout the day, that takes the patient’s renal function into account. Full regimen, sequencing, and clinical targets are in the complete protocol below.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.kint.2024.07.010

We suggest adapting water intake, spread throughout the day, to achieve at least 2–3 liters of water intake per day in people with ADPKD and an eGFR ≥30 ml/min per 1.73 m2 without contraindications to excreting a solute load (2D).

View source ↗